NCT06380153 - To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 7, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions

Psoriasis

Interventions

DRUG

Hemay005

15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1

Trial Locations (1)

RECRUITING

Union Hospital of Tongji Medical College; Huazhong University of Science and Technology, Wuhan